Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma
What this study shows
In mouse kidney tumours, active phosphorylated mTOR and total mTOR protein followed a 24-hour rhythm, set by the clock through the ubiquitin ligase Fbxw7. Giving everolimus when mTOR was high improved survival compared with other dosing times. Same drug, same dose - the clock time of dosing changed the outcome.
Abstract
ShowHide
Circadian clock systems regulate many biologic functions, including cell division and hormone secretion in mammals. In this study, we explored the effects of circadian control on the pivot cell growth regulatory mTOR, the activity of which is deregulated in tumor cells compared with normal cells. Specifically, we investigated whether the antitumor effect of an mTOR inhibitor could be improved by changing its dosing schedule in RenCa tumor-bearing mice.
Read the full abstract on PubMed →At a glance
ShowHide
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: RenCa tumour-bearing mice; NIH 3T3 cells); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | RenCa tumour-bearing mice; NIH 3T3 cells |
| Journal | Cancer Research |
| Year | 2013 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1158/0008-5472.CAN-12-3241 · PMID 24253377 |
Where this study fits
How this study connects to the pathway map, open questions, people and other studies in the Atlas.
People in the Atlas
-
Pharmacologist at Daiichi University of Pharmacy in Fukuoka who studies how the body clock sets the daily rhythm of mTOR in tumours and how to time cancer drugs to match it
-
Works on the body clock and drug timing (chronopharmacology), including how circadian rhythms control mTOR in cancer cells.
More: 8 other authors
No profile yet: Matsunaga N, Fujioka T, Okazaki F, Akagawa Y, Tsurudome Y, Ono M, Kuwano M, Koyanagi S
Related studies
- A SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer
TAN2026 · 2026 · Shares: Renal cell carcinoma (RCC), Everolimus
- H Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
MOT2008 · 2008 · Shares: Renal cell carcinoma (RCC), Everolimus
- R Defining the role of mTOR in cancer
GUE2007 · 2007 · Shares: Renal cell carcinoma (RCC), mTOR
- H Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
HUD2007 · 2007 · Shares: Renal cell carcinoma (RCC), mTOR
- A
More related studies
- H
- S Targeting ageing with rapamycin and its derivatives in humans: a systematic review
LEE2024 · 2024 · Shares: mTOR, Everolimus
- H
- H Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
KRU2010 · 2010 · Shares: mTOR, Everolimus
- H
- H
- H
- H
Topics
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Everolimus dosed at different times of day |
| Target | mTOR; Fbxw7; DBP |
| Model | Mouse |
| Effect | Dosing everolimus at the mTOR peak improved survival of tumour-bearing mice |
Thank you. Your answer was counted anonymously.